Five Prime Therapeutics

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 60 in Five Prime Therapeutics

  1. Five Prime Therapeutics (FPRX) Initiated As a SellRead the original story w/Photo

    11 hrs ago | TheStreet.com

    ... a ratings score of D. TheStreet Ratings Team has this to say about their recommendation: "We rate FIVE PRIME THERAPEUTICS INC (FPRX) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and ...

    Comment?

  2. TiGenix Publishes Transparency Notification Pursuant To Article 14 Of The Law Of May 2, 2007Read the original story

    Friday Oct 17 | BioSpace

    October 17, 2014 - TiGenix NV publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions. It concerns a notification made by the related companies Roche Holding AG / Roche Finanz AG following the passive crossing below the 3% threshold on November 22, 2013 by the group as a whole .

    Comment?

  3. Roche sales up 2%, boosted by cancer drugsRead the original story w/Photo

    Thursday Oct 16 | MarketWatch

    Roche Holding AG on Thursday reported a nearly 2% jump in third-quarter sales, beating analyst expectations as the pharmaceutical giant's cancer drugs continued to power its performance. Basel-based Roche said group sales in the quarter ended September rose 1.8% to 11.78 billion Swiss francs from 11.57 billion francs in the same quarter a year earlier.

    Comment?

  4. Roche Lifted by Cancer DrugsRead the original story w/Photo

    Wednesday Oct 15 | Wall Street Journal

    Roche Holding AG on Thursday reported a nearly 2% jump in third-quarter sales as the pharmaceutical giant's cancer drugs continued to power its performance. Basel-based Roche said group sales in the quarter rose 1.8% to 11.78 billion Swiss francs from 11.57 billion francs in the same quarter a year earlier.

    Comment?

  5. Five Prime Therapeutics, Inc. Appoints To Its Board Of DirectorsRead the original story

    Friday Oct 3 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Bill Ringo, a strategic advisor at Sofinnova Ventures, to the company's Board of Directors. The addition of Mr. Ringo increases the number of directors from eight to nine.

    Comment?

  6. Five Prime Therapeutics Appoints Bill Ringo to Its Board of DirectorsRead the original story

    Thursday Oct 2 | Hispanic Business

    "We are delighted to add Bill to the Five Prime board," said , M.D., Ph.D., president and chief executive officer of Five Prime. "Bill's extensive drug development experience and knowledge, especially in the field of oncology, will be invaluable as we continue to expand our research and grow our product pipeline."

    Comment?

  7. Database shows $3.5 billion in industry ties to doctors, hospitalsRead the original story w/Photo

    Tuesday Sep 30 | Los Angeles Times

    Government data show that City of Hope, a major cancer treatment center in Duarte, received $122.5 million in royalty income from drug maker Genentech, a unit of Swiss giant Roche Holding. Above, Genentech headquarters in South San Francisco.

    Comment?

  8. Five Prime Therapeutics, Inc. Appoints As Vice President Of Global Clinical DevelopmentRead the original story

    Sep 18, 2014 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Robert Sikorski, M.D., Ph.D., as Vice President of Global Clinical Development. Dr. Sikorski will oversee the global clinical development activities for Five Prime's product candidates.

    Comment?

  9. GlaxoSmithKline Exercises Option For Five Prime Therapeutics, Inc.'s Skeletal Muscle DrugsRead the original story

    Sep 16, 2014 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced today that GlaxoSmithKline has exercised its option to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target that Five Prime discovered using its proprietary library of human extracellular proteins and target screening and discovery capabilities. Five Prime and GSK established the collaboration in 2010 to enable the potential discovery, development and commercialization of drug targets for skeletal muscle diseases using Five Prime's protein target discovery platform.

    Comment?

  10. GSK Licenses Five Prime Muscle Disease TargetRead the original story w/Photo

    Sep 16, 2014 | Contract Pharma Breaking News

    GlaxoSmithKline has exercised its option to obtain an exclusive, worldwide license to products associated with an undisclosed muscle disease target discovered using Five Prime Therapeutics screening and discovery capabilities. Five Prime will receive a $1.5 million exercise fee and is entitled to receive as much as $122.5 million in preclinical, development and commercial-related milestones and royalties on sales.

    Comment?

  11. GSK exercises Five Prime option for skeletal muscle drugsRead the original story w/Photo

    Sep 15, 2014 | Business Journal

    GlaxoSmithKline exercised an option for an exclusive license for muscle disease treatments developed by Five Prime Therapeutics Inc. , the companies said Monday. The potential $124 million collaboration between South San Francisco's Five Prime and GlaxoSmithKline began in 2010 and focuses on skeletal muscle diseases drugs that use Five Prime's protein target discovery platform.

    Comment?

  12. Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline...Read the original story

    Sep 15, 2014 | Hispanic Business

    Five Prime and GSK established the collaboration in 2010 to enable the potential discovery, development and commercialization of drug targets for skeletal muscle diseases using Five Prime's protein target discovery platform. By exercising its option, GSK will receive exclusive rights to develop and commercialize products globally, at its own cost and expense, that incorporate or are directed to the selected target.

    Comment?

  13. Five Prime Therapeutics, Inc. To Present At Morgan Stanley 2014 Global Healthcare ConferenceRead the original story

    Sep 4, 2014 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Morgan Stanley 2014 Global Healthcare Conference on Tuesday, September 9 at 5:15 PM Eastern Time. The conference will take place at the Grand Hyatt in New York City.

    Comment?

  14. Biotech Advancements in Innovative Cancer Therapy Reveal Developing...Read the original story

    Sep 4, 2014 | Sys-Con Media

    Biotech companies seeking to make progress with Hepatocellular Carcinoma therapies and other cancer therapeutics: GenSpera Inc. , Roche Holding AG , Eli Lilly and Company , Amgen Inc. , Johnson and Johnson and Infinity Pharmaceuticals Inc. GenSpera, Inc. , a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization's International Nonproprietary Name group has recommended the generic name "mipsagargin" for its lead drug candidate, also known as G-202, currently in Phase II clinical trials for hepatocellular carcinoma and glioblastoma . Mipsagargin was also recommended by the United States Adopted Names Council of the American Medical Association.

    Comment?

  15. Five Prime Therapeutics to Present at Morgan Stanley 2014 Global Healthcare ConferenceRead the original story

    Sep 3, 2014 | Hispanic Business

    The live webcast will be accessible at or directly at .

    Comment?

  16. New DealsRead the original story w/Photo

    Aug 27, 2014 | Law.com

    Burger King Worldwide Inc. and Canadian chain Tim Hortons Inc. have agreed to an $11.4 billion tie-up that would send the combined company's headquarters north in what may be the most visible corporate tax inversion yet.

    Comment?

  17. Wall Street up, S&P 500 sets record high but fails to hold 2,000 markRead the original story

    Aug 25, 2014 | Buenos Aires Herald

    The S&P 500 was unable to hold the 2,000 mark after moving above the milestone level for the first time today, but still managed to close at a record high, buoyed by financials and biotechnology stocks.

    Comment?

  18. Roche to Buy InterMune for $8.3 Billion, Adding Lung DrugRead the original story

    Aug 25, 2014 | The Washington Post

    Roche Holding AG, the world's largest maker of cancer drugs, is strengthening its portfolio of medicines for respiratory ailments with an agreement to buy InterMune Inc. for $8.3 billion in cash.

    Comment?

  19. US Stocks: SandP 500 sets record high but fails to hold 2,000 markRead the original story

    Aug 25, 2014 | Express India

    Summary The S&P 500 was unable to hold the 2,000 mark after moving above the milestone level for the first time on Monday, but still managed to close at a record high, buoyed by financials and biotechnology stocks.

    Comment?

  20. Global shares rally, S&P 500 tops 2,000 for the first timeRead the original story

    Aug 25, 2014 | Buenos Aires Herald

    The S&P 500 vaulted above 2,000 for the first time today, with financials and biotechnology stocks lifting the benchmark index to a new record as investors bet on equities as a preferred asset over bonds.

    Comment?